DK0580459T3 - Substituerede phenylimidazolidiner, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf - Google Patents

Substituerede phenylimidazolidiner, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf

Info

Publication number
DK0580459T3
DK0580459T3 DK93401361T DK93401361T DK0580459T3 DK 0580459 T3 DK0580459 T3 DK 0580459T3 DK 93401361 T DK93401361 T DK 93401361T DK 93401361 T DK93401361 T DK 93401361T DK 0580459 T3 DK0580459 T3 DK 0580459T3
Authority
DK
Denmark
Prior art keywords
pharmaceuticals
halogen
image
oxygen
substituted
Prior art date
Application number
DK93401361T
Other languages
English (en)
Inventor
Francois Goubet
Daniel Philibert
Martine Gaillard-Kelly
Jean-Georges Teutsch
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK0580459T3 publication Critical patent/DK0580459T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
DK93401361T 1992-07-08 1993-05-28 Substituerede phenylimidazolidiner, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf DK0580459T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR929208431A FR2693461B1 (fr) 1992-07-08 1992-07-08 Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.

Publications (1)

Publication Number Publication Date
DK0580459T3 true DK0580459T3 (da) 2001-06-11

Family

ID=9431679

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93401361T DK0580459T3 (da) 1992-07-08 1993-05-28 Substituerede phenylimidazolidiner, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf

Country Status (17)

Country Link
EP (1) EP0580459B1 (da)
JP (1) JP3845455B2 (da)
KR (1) KR100294383B1 (da)
CN (1) CN1044234C (da)
AT (1) ATE200077T1 (da)
AU (1) AU670942B2 (da)
CA (1) CA2097248A1 (da)
DE (1) DE69330058T2 (da)
DK (1) DK0580459T3 (da)
ES (1) ES2155067T3 (da)
FR (1) FR2693461B1 (da)
GR (1) GR3035768T3 (da)
HU (1) HUT64527A (da)
PT (1) PT580459E (da)
RU (1) RU2116298C1 (da)
UA (1) UA34428C2 (da)
ZA (1) ZA933786B (da)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2724169B1 (fr) * 1994-09-06 1997-01-03 Roussel Uclaf Nouvelles phenylimidazolidines eventuellement substituees, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
TW521073B (en) * 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) * 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
AU726572B2 (en) * 1994-02-16 2000-11-09 Aventis Pharma S.A. Cosmetics or pharmaceutical compositions consisting of liposomes
FR2716110B1 (fr) 1994-02-16 1996-04-05 Roussel Uclaf Compositions cosmétiques ou pharmaceutiques comprenant des liposomes.
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741342B1 (fr) * 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
WO2000024366A1 (de) * 1998-10-23 2000-05-04 Aventis Pharma Deutschland Gmbh Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
JP4621335B2 (ja) 2000-06-28 2011-01-26 セイコーエプソン株式会社 情報端末用プリンタユニット
AU2002360932A1 (en) * 2001-11-23 2003-06-10 Schering Aktiengesellschaft Piperazine derivatives destabilising androgen receptors
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
DE10218963A1 (de) * 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
US20060025589A1 (en) * 2002-10-01 2006-02-02 Jean Binet 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2845383B1 (fr) * 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
DE10322108B4 (de) * 2003-05-09 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004111012A1 (ja) * 2003-06-12 2004-12-23 Chugai Seiyaku Kabushiki Kaisha イミダゾリジン誘導体
ATE502298T1 (de) 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
TW200612920A (en) * 2004-08-03 2006-05-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivatives
TW200621723A (en) * 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2013203255C1 (en) * 2005-05-13 2017-01-19 The Regents Of The University Of California Diarylthiohydantoin compounds
KR101169832B1 (ko) * 2005-05-13 2012-07-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
SI1891038T1 (sl) * 2005-05-13 2009-04-30 Lilly Co Eli Substituirani n-arilpirolodini kot selektivni modulatorji androgenskega receptorja
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
EP3412290B1 (en) 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN101460467B (zh) * 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
JP5535925B2 (ja) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アンドロゲン受容体調節物質としてのジアリールヒダントイン化合物
WO2009097996A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms
EP2242747A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
ES2488990T3 (es) 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
CA2725680A1 (en) 2008-05-30 2009-12-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2010069519A1 (en) 2008-12-18 2010-06-24 Merz Pharma Gmbh & Co. Kgaa Topical compositions comprising at least one active ingredient poorly soluble in water and biopolymers such as hyaluronic acid with a pka-value between 5-7
SG172986A1 (en) 2009-02-10 2011-08-29 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
FR2954316B1 (fr) 2009-12-23 2014-01-03 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954315B1 (fr) 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
EP2531029B1 (en) 2010-02-04 2016-10-19 Radius Health, Inc. Selective androgen receptor modulators
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
BR112012021406B1 (pt) * 2010-02-24 2021-08-10 Medivation Prostate Therapeutics Llc Processos para a síntese dos compostos de diariltioidantoína e diarilidantoína
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
CN103965112A (zh) * 2014-05-13 2014-08-06 上海孚一生物科技有限公司 一种具有抗雄激素活性的化合物、制备方法及其应用
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4916937B1 (da) * 1970-01-21 1974-04-25
US3823240A (en) * 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
US3923994A (en) * 1973-07-13 1975-12-02 Smithkline Corp Anti-arthritic compositions comprising a 3-aryl 2-thiohydantoin and methods of producing anti-arthritic acitvity
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
MC1220A1 (fr) * 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
DE2933917A1 (de) * 1979-08-22 1981-03-26 Basf Ag, 67063 Ludwigshafen 5-imino-imidazolidin-2-one und diese enthaltende herbizide.
US4753957A (en) * 1981-09-28 1988-06-28 Rohm And Haas Company Substituted 2,4-imidazolidinediones and fungicidal compositions
EP0091596B1 (de) * 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en) * 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
FR2656302B1 (fr) * 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
FR2671348B1 (fr) * 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.

Also Published As

Publication number Publication date
FR2693461B1 (fr) 1994-09-02
JPH0673017A (ja) 1994-03-15
EP0580459A1 (fr) 1994-01-26
RU2116298C1 (ru) 1998-07-27
HU9301585D0 (en) 1993-09-28
AU670942B2 (en) 1996-08-08
UA34428C2 (uk) 2001-03-15
KR940005582A (ko) 1994-03-21
ATE200077T1 (de) 2001-04-15
EP0580459B1 (fr) 2001-03-28
PT580459E (pt) 2001-07-31
ZA933786B (en) 1994-05-30
CA2097248A1 (fr) 1994-01-09
AU3987693A (en) 1994-01-13
CN1044234C (zh) 1999-07-21
KR100294383B1 (ko) 2001-09-17
ES2155067T3 (es) 2001-05-01
JP3845455B2 (ja) 2006-11-15
CN1081182A (zh) 1994-01-26
DE69330058T2 (de) 2001-09-06
GR3035768T3 (en) 2001-07-31
FR2693461A1 (fr) 1994-01-14
DE69330058D1 (de) 2001-05-03
HUT64527A (en) 1994-01-28

Similar Documents

Publication Publication Date Title
DK0580459T3 (da) Substituerede phenylimidazolidiner, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
DK0494819T3 (da) Hidtil ukendte phenylimidazolidiner, deres fremstilling, anvendelse som lægemidler samt farmaceutiske præparater med indhold heraf
DE69823344D1 (de) Substituierte benzimidazol-derivaten und ihre verwendung zur behandlung retroviraler infektionen
AP1468A (en) Hiv inhibiting pyrimidine derivatives.
HUP0003731A2 (hu) 4-Bróm- vagy 4-jód-fenil-amino-benzhidroxámsav-származékok és ilyen vegyületek MEK gátlóként való alkalmazása
AP1475A (en) Trisubstituted 1, 3, 5-triazine derivatives for treatment of HIV infections.
NO934719D0 (no) Hemmere av HIV-protease som er nyttige for behandling av AIDS
DK1163212T3 (da) Amidderivater
DE69402689D1 (de) 4-Benzoyl-Isoxazol Derivate, deren Herstellung und deren Verwendung als Herbizide
DK0382687T3 (da) N-Holdige heterocyliske derivater, som har en ondenseret benzenring
DE60001586D1 (de) Diphenyl-piperidin derivate
DE69431316T2 (de) Amidderivate und ihre therapeutische Verwendung
HUP0400464A2 (hu) Adenozin analógok inzulinrezisztencia szindróma és diabétesz kezelésére
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
ATE500231T1 (de) Hiv hemmende pyrimidin derivate
KR950002761A (ko) 강박 반응 장애 치료제 제조용으로서의 n-(피리디닐)-1h-인돌-1-아민의 용도
EA200100534A1 (ru) Производные 2,4-дизамещенного триазина
BR9712763A (pt) Derivados de benzenosulfonamida e medicamentos que contêm tais derivados
NO20000114D0 (no) 2,4,4-trisubstituerte-1,3-diokolan-antifungale midler
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
TH3325EX (th) เฟนนิลเบนโซอิลยูเรีย
TH4707EX (th) เฟนนิลเบนโซอิลยูเรีย
TH65065A (th) สารประกอบเคมี
TH3364A (th) เฟนนิลเบนโซอิลยูเรีย